Drug Type Monoclonal antibody |
Synonyms Lendalizumab (USAN), Olendalizumab (USAN), lendalizumab + [1] |
Target |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Antiphospholipid Syndrome | Phase 2 | - | - | |
Graft Rejection | Phase 2 | - | - | |
Graft versus host disease in gastrointestinal tract | Preclinical | US | 14 Nov 2014 | |
Antiphospholipid Syndrome | Preclinical | BR | - | |
Antiphospholipid Syndrome | Preclinical | GB | - | |
Antiphospholipid Syndrome | Preclinical | JP | - | |
Antiphospholipid Syndrome | Preclinical | IT | - | |
Antiphospholipid Syndrome | Preclinical | US | - | |
Antiphospholipid Syndrome | Preclinical | ES | - | |
Antiphospholipid Syndrome | Preclinical | FR | - |
Phase 2 | 25 | (ALXN1007 10 mg/kg Once Weekly) | oziogqgltl(obhdgeqqax) = qhrxiqtref tgauzlggww (bvteitrglf, xisbatnuce - piqsxtafik) View more | - | 06 Oct 2017 | ||
(ALXN1007 20 mg/kg Once Weekly) | oziogqgltl(obhdgeqqax) = kyacuujtmo tgauzlggww (bvteitrglf, jstvbtbpxg - nzqvfmsvfo) View more | ||||||
Phase 2 | 9 | lhclabclrd(fvubphsair) = wobxzmpqmv werswhlidu (eindhcnkni, vyajkhhphf - ejwefyjrdp) View more | - | 13 Jul 2017 |